Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

Published:2016-05 Issue:5 Volume:69 Page:834-840
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Massard Christophe,Penttinen Heidi M.,Vjaters Egils,Bono Petri,Lietuvietis Vilnis,Tammela Teuvo L.,Vuorela Annamari,Nykänen Pirjo,Pohjanjousi Pasi,Snapir Amir,Fizazi Karim

Publisher

Elsevier BV

Subject

Urology

Reference16 articles.

1. Prostate cancer: ESMO Consensus Conference Guidelines 2012;Horwich;Ann Oncol,2013

2. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer;Zobniw;Res Rep Urol,2014

3. Sequencing of agents for castration-resistant prostate cancer;Hurwitz;Oncology (Williston Park),2013

4. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol,2012

5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact;Expert Opinion on Drug Metabolism & Toxicology;2024-05-22

2. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol;European Urology Oncology;2024-05

3. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS;The Oncologist;2024-02-23

4. Safety profile of darolutamide versus placebo: a systematic review and meta-analysis;Prostate Cancer and Prostatic Diseases;2023-12-14

5. Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives;Biomedicine & Pharmacotherapy;2023-12